Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04396756
Registration number
NCT04396756
Ethics application status
Date submitted
6/05/2020
Date registered
21/05/2020
Date last updated
3/06/2024
Titles & IDs
Public title
Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
Query!
Scientific title
A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)
Query!
Secondary ID [1]
0
0
INTEGRIS-IPF
Query!
Secondary ID [2]
0
0
PLN-74809-IPF-202
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - PLN-74809
Treatment: Drugs - Placebo
Experimental: Placebo - Placebo
Experimental: PLN-74809 Dose Level 1 (Part A) - PLN-74809 Dose Level 1 (Part A) - 4 weeks
Experimental: PLN-74809 Dose Level 2 (Part A) - PLN-74809 Dose Level 2 (Part A) - 4 weeks
Experimental: PLN-74809 Dose Level 2 (Part B) - PLN-74809 Dose Level 2 (Part B) - 12 weeks
Experimental: PLN-74809 - Dose Level 3 (Part C) - PLN-74809 Dose Level 3 (Part C) - 12 weeks
Experimental: PLN-74809 - Dose Level 4 (Part C) - PLN-74809 Dose Level 4 (Part C) - 12 weeks
Experimental: PLN-74809 - Dose Level 5 (Part D) - PLN-74809 Dose Level 5 (Part D) - = 24 weeks
Treatment: Drugs: PLN-74809
PLN-74809
Treatment: Drugs: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part A - Number of Participants With Treatment-Emergent Adverse Events
Query!
Assessment method [1]
0
0
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 14 days after permanent discontinuation of study drug.
Query!
Timepoint [1]
0
0
Up to 4 weeks
Query!
Primary outcome [2]
0
0
Part B, C, D - Number of Participants With Treatment-Emergent Adverse Events
Query!
Assessment method [2]
0
0
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 14 days after permanent discontinuation of study drug.
Query!
Timepoint [2]
0
0
Up to 12 weeks
Query!
Primary outcome [3]
0
0
Part D - Number of Participants With Treatment-Emergent Adverse Events
Query!
Assessment method [3]
0
0
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 14 days after permanent discontinuation of study drug.
Query!
Timepoint [3]
0
0
Up to 48 weeks
Query!
Primary outcome [4]
0
0
Part A - Number of Participants With Serious Treatment-Emergent Adverse Events
Query!
Assessment method [4]
0
0
An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.
Query!
Timepoint [4]
0
0
Up to 4 weeks
Query!
Primary outcome [5]
0
0
Part B, C, D - Number of Participants With Serious Treatment-Emergent Adverse Events
Query!
Assessment method [5]
0
0
An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.
Query!
Timepoint [5]
0
0
Up to 12 weeks
Query!
Primary outcome [6]
0
0
Part D - Number of Participants With Serious Treatment-Emergent Adverse Events
Query!
Assessment method [6]
0
0
An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.
Query!
Timepoint [6]
0
0
Up to 48 weeks
Query!
Secondary outcome [1]
0
0
Part A - Assessment of PLN-74809 Total Plasma Concentrations
Query!
Assessment method [1]
0
0
Part A - Assessment of PLN-74809 Total Plasma Concentrations Week 4, 1 Hour Post Dose
Query!
Timepoint [1]
0
0
Week 4, 1 Hour Post Dose
Query!
Secondary outcome [2]
0
0
Part B, C, D - Assessment of PLN-74809 Total Plasma Concentrations
Query!
Assessment method [2]
0
0
Part B, C, D - Assessment of PLN-74809 Total Plasma Concentrations Week 12, 2 Hours Post Dose
Query!
Timepoint [2]
0
0
Week 12, 2 Hours Post Dose
Query!
Secondary outcome [3]
0
0
Part D - Assessment of PLN-74809 Total Plasma Concentrations
Query!
Assessment method [3]
0
0
Part D - Assessment of PLN-74809 Total Plasma Concentrations Week 24, 2 Hours Post Dose
Query!
Timepoint [3]
0
0
Week 24, 2 Hours Post Dose
Query!
Eligibility
Key inclusion criteria
- Diagnosis of IPF based upon the Fleischner Society guidelines within 3 years from
Screening (Part A) or based on ATS/ERS/JRS/ALAT 2018 guidelines within 5 years from
Screening (Part B, C & D)
- FVC % of predicted =45%
- DLco (hemoglobin-adjusted) =30%
- Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,
if on a stable dose for at least 3 months
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents
not approved for that indication by the FDA
- Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC
ratio <0.7 at Screening
- Clinical evidence of active infection, including but not limited to bronchitis,
pneumonia, sinusitis that can affect FVC measurement or IPF progression
- Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months
of Screening
- Smoking of any kind within 3 months of Screening
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/03/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
15/02/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
120
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Tennessee
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Leuven
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Ontario
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Quebec
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Milan
Query!
Country [15]
0
0
Netherlands
Query!
State/province [15]
0
0
EJ
Query!
Country [16]
0
0
Netherlands
Query!
State/province [16]
0
0
SZ
Query!
Country [17]
0
0
New Zealand
Query!
State/province [17]
0
0
Auckland
Query!
Country [18]
0
0
New Zealand
Query!
State/province [18]
0
0
Christchurch
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pliant Therapeutics, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Phase 2a, multicenter, 4-part, randomized, double-blind, dose-ranging, placebo-controlled
study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in
participants with idiopathic pulmonary fibrosis.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04396756
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pliant Therapeutics Medical Monitor
Query!
Address
0
0
Pliant Therapeutics, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04396756
Download to PDF